Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EVENT HORIZON III who wrote (163)	1/24/2003 2:16:51 PM
From: Jibacoa	Read Replies (1) of 684

VICL According to its latest report, it had $119M as of Sep.30 down from $134M on Dec.31 2001 ($5.92/share based on 20.1M shares) They were expecting a 32M loss for the year (Including the $4.2 million write-down from the investment in VGI) What I don't like about VICL is that the insiders don't hold any shares outright. I remember a few years back (may be 6 or 8 yrs.<g>) when Michael Murphy on a Barrons Round Table said he expected the company would be at the $100 level within one year.It was not able to get past the $18 level for several years until it hit $73.50 in Feb.2000. (Just before the BB.<g>) They said in November that they were expecting to have interim data from the high-dose Phase II trial of Allovectin in time for the May 2003 annual meeting of ASCO. They also are planning to concentrate their resources on their infectious disease vaccine development,including Ebola, under a manufacturing contract with NIAID and anthrax, in collaboration with Ohio State University and a grant from the NIAID. The stock is down only 1.4% today on low volume of 14.8K, but it seems like it may retest its December or even its October and September Ls. siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next